72 assets in Burkitt Lymphoma

Therapeutic assets addressing Burkitt Lymphoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Lentivirus Vector Ccr5 Shrna Burkitt Lymphoma	AIDS Malignancy Consortium	P1/2	CCC (48)
Mercaptopurine Anhydrous Burkitt Lymphoma	M.D. Anderson Cancer Center	P1/2	CCC (48)
Fruquintinib Burkitt Lymphoma	Immunitas Therapeutics	P1/2	CC (45)
Immunoglobulin G1-Kappa, Anti-[Homo Sapiens Klrb1 (Killer Cell Lectin Like Receptor B1, Nkr-P1A, Natural Killer Cell Surface Protein P1A, Clec5B, Cd161)], Homo Sapiens Monoclonal Antibody; Gamma1 Heavy Chain Homo Sapiens (1-450) [Vh (Homo Sapiens Ighv3-2301 (96.9%) -(Ighd) -Ighj401 (85.7%), Q120>R (113), Cdr-Imgt [8.8.14] (26-33.51-58.97-110)) (1-121) -Homo Sapiens Ighg101, G1M17,1 Ch1 K120, Ch3 D12, L14, G1V29 Ch2 A84.4 (Ch1 K120 (218) (122-219), Hinge 1-15 (220-234), Ch2 G1V29 Ch2 N84.4>A (301) (235-344), Ch3 D12 (360), L14 (362) (345-449), Chs K2>Del (450)) (122-450)], (224-214')-Disulfide With Kappa Light Chain Homo Sapiens (1'-214') [V-Kappa (Homo Sapiens Igkv1-1201 (94.7%) -Igkj401 (91.7%), Cdr-Imgt [6.3.9] (27'-32'.50'-52'.89'-97')) (1'-107') -Homo Sapiens Igkc01 (100%), Km3, A45.1 (153'), V101 (191') (108'-214')]; Dimer (230-230'':233-233'')-Bisdisulfide, Produced In Chinese Hamster Ovary (Cho) Cells, Cell Line Cho-K1 Lacking The Glutamine Synthetase (Gs-Ko) Gene, Non-Glycosylated Burkitt Lymphoma	Immunitas Therapeutics	P1/2	CC (45)
Pidnarulex Burkitt Lymphoma	National Cancer Institute (NCI)	P1/2	CC (45)
Polatuzumab Vedotin Burkitt Lymphoma	New York Medical College	P1/2	CC (45)
Vnx-101 Burkitt Lymphoma	Vironexis Biotherapeutics Inc.	P1/2	CC (45)
ace1831 Burkitt Lymphoma	Acepodia Biotech, Inc.	P1	CC (44)
Loncastuximab Tesirine Burkitt Lymphoma	Medical College of Wisconsin	P1	CC (44)
Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tcm-Enriched T Cells Burkitt Lymphoma	City of Hope Medical Center	P1	CC (43)
Autologous Cd19Car-Cd28-Cd3Zeta-Egfrt-Expressing Tn/Mem-Enriched T-Lymphocytes Burkitt Lymphoma	City of Hope Medical Center	P1	CC (43)
cd22 car-t Burkitt Lymphoma	Stanford University	P1	CC (41)
Copanlisib Burkitt Lymphoma	National Cancer Institute (NCI)	P1	CC (41)
lv20.19 car t cells Burkitt Lymphoma	Medical College of Wisconsin	P1	CC (41)
Pirtobrutinib Burkitt Lymphoma	Medical College of Wisconsin	P1	CC (41)
Polatuzumab Burkitt Lymphoma	National Cancer Institute (NCI)	P1	CC (41)
Pomalidomide Burkitt Lymphoma	National Cancer Institute (NCI)	P1	CC (41)
Sgr-1505 Burkitt Lymphoma	Schrödinger, Inc.	P1	CC (41)
Anti-Cd19/Cd22 Car-T Cells Burkitt Lymphoma	First Affiliated Hospital Xi'an Jiaotong University	Early P1	C (38)

Showing 51 to 72 of 72 assets

PreviousPage 2 of 2Next